Healthcare / Medical DevicesHKSE
$9.37
-0.05 (-0.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $154.4M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.4B
P/E
25.3x
↑EV/EBITDA
16.8x
↑ROE
10.3%
↑Gross Margin
73.5%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.0%
FCF CAGR
-4.3%
FCF margin
19.5%
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $790.5M · net income $184.5M · FCF $154.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $790.5M | $790.5M | $761.8M | $665.6M | $547.4M |
| Net Income | $184.5M | $184.5M | $254.2M | $145.5M | $-21.8M |
| EBITDA | $290.7M | $290.7M | $364.0M | $221.6M | $151.7M |
| EPS | — | — | 0.44 | 0.25 | -0.04 |
| Gross Margin | 73.5% | 73.5% | 73.0% | 76.9% | 71.8% |
| Operating Margin | 38.7% | 38.7% | 39.3% | 29.8% | 24.3% |
| Net Margin | 23.3% | 23.3% | 33.4% | 21.9% | -4.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.04 | 0.06 |
| Current Ratio | 6.01 | 6.01 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $154.4M | $154.4M | $227.8M | $-48.8M | $175.9M |
| Returns | |||||
| ROE | 10.3% | 10.3% | 14.9% | 8.9% | -1.5% |
| Valuation | |||||
| P/E | 25.32 | 25.32 | 18.59 | 38.16 | — |
| EV/EBITDA | 16.76 | 16.76 | 11.40 | 22.11 | 75.98 |
| P/B | 3.04 | 3.04 | 2.77 | 3.40 | 8.33 |
| Growth & Yield | |||||
| Revenue Growth | 3.8% | 3.8% | 14.4% | 21.6% | — |
| EPS Growth | — | — | 76.0% | 725.0% | — |
| Dividend Yield | 1.5% | 1.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.0%
Start / end P/E
n/dx → n/dx
EPS bridge
0.44 → n/d
Residual
-6.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.